Voya Investment Management LLC decreased its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 81.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,505 shares of the company's stock after selling 70,274 shares during the quarter. Voya Investment Management LLC's holdings in RxSight were worth $533,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. increased its position in RxSight by 4.2% in the fourth quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company's stock worth $81,946,000 after buying an additional 96,464 shares in the last quarter. Artisan Partners Limited Partnership increased its position in RxSight by 32.6% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company's stock worth $53,345,000 after buying an additional 381,389 shares in the last quarter. Geode Capital Management LLC increased its position in RxSight by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 830,758 shares of the company's stock worth $28,568,000 after buying an additional 13,641 shares in the last quarter. DF Dent & Co. Inc. purchased a new stake in RxSight in the fourth quarter worth about $14,524,000. Finally, Renaissance Technologies LLC increased its position in RxSight by 102.9% in the fourth quarter. Renaissance Technologies LLC now owns 361,500 shares of the company's stock worth $12,428,000 after buying an additional 183,300 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on RXST. Bank of America restated an "underperform" rating and issued a $22.00 price target (down previously from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. Needham & Company LLC reaffirmed a "buy" rating and issued a $43.00 price objective on shares of RxSight in a research note on Thursday, April 3rd. Wells Fargo & Company dropped their price objective on RxSight from $35.00 to $22.00 and set an "equal weight" rating for the company in a research note on Thursday, April 3rd. UBS Group lowered RxSight from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Finally, JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $17.00 price objective (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $37.60.
Check Out Our Latest Research Report on RxSight
Insider Activity
In other news, Director Tamara Fountain sold 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now directly owns 24,793 shares of the company's stock, valued at $637,428.03. This trade represents a 22.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 9.36% of the company's stock.
RxSight Stock Up 5.3%
RxSight stock traded up $0.69 during midday trading on Monday, reaching $13.75. 1,902,293 shares of the stock traded hands, compared to its average volume of 661,815. The stock's fifty day moving average is $19.02 and its 200-day moving average is $31.01. RxSight, Inc. has a 12 month low of $13.03 and a 12 month high of $64.50. The stock has a market cap of $558.76 million, a P/E ratio of -16.57 and a beta of 1.32.
RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $37.90 million during the quarter, compared to analyst estimates of $38.74 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company's revenue for the quarter was up 28.5% on a year-over-year basis. During the same period last year, the company earned ($0.25) EPS. On average, equities analysts predict that RxSight, Inc. will post -0.7 EPS for the current fiscal year.
About RxSight
(
Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
See Also
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
